Efficacy News and Research

RSS

Transparency Life receives SBIR program grant to fund Phase 2a proof-of-concept study for MS

Transparency Life Sciences, LLC (TLS), the world's first clinical-stage drug development company based on open innovation, today announced that it has received a Small Business Innovation Research (SBIR) program grant to fund a Phase 2a proof-of-concept study testing the utility of the ACE inhibitor lisinopril as an adjunctive therapy for multiple sclerosis (MS).

8 Sep 2014

BMC receives grant from Cardinal Health Foundation to help improve effectiveness of patient care

The Cardinal Health Foundation announced it has awarded Virginia R. Litle, MD, a Thoracic Surgeon at Boston Medical Center (BMC) grant funding from the E3 Grant Program to implement best practices and help improve the effectiveness, efficiency and excellence of patient care.

8 Sep 2014

Non-invasive delivery of drugs for effective pain relief

Individuals who are squeamish about injections or are looking for a way to let collagen penetrate deeper into the skin may soon have a solution that is faster, more effective and painless.

8 Sep 2014

New immuno-oncology drug helps body's own immune system to fend off cancer

According to an August 25 Reuters report, the U.S. Food and Drug Administration is likely to approve Merck & Co.'s highly anticipated immuno-oncology drug, pembrolizumab, as a treatment for melanoma well ahead of a late October deadline.

8 Sep 2014

New antifungal drug effective against invasive mold disease in cancer patients with less adverse effects

A newly developed antifungal, isavuconazole, is as effective as an existing drug, voriconazole, against invasive mold disease in cancer patients with less adverse effects, according to phase 3 clinical data presented at the 54th Interscience Conference on Antimicrobial Agents and Chemotherapy, an infectious disease meeting of the American Society for Microbiology.

8 Sep 2014

Soligenix acquires novel orphan drug candidate for treatment of CTCL

Soligenix, Inc., a late-stage biopharmaceutical company developing products that address unmet medical needs in the areas of inflammation, oncology and biodefense, announced today the acquisition of a novel orphan drug candidate, known as SGX301 (synthetic hypericin).

8 Sep 2014

Scientists apply iPS cell technology to Huntington's disease transgenic monkey model

Creating induced pluripotent stem cells or iPS cells allows researchers to establish "disease in a dish" models of conditions ranging from Alzheimer's disease to diabetes.

8 Sep 2014

Combination miRNA therapy offers promising therapeutic avenue for non-small-cell lung cancer

Micro RNAs (miRNA) have recently emerged as key therapeutic agents against cancers and are actively being evaluated in pre-clinical models of various cancers as well as in human clinical trials.

8 Sep 2014

New actinic keratoses data presented at the 15th World Congress of Cancers of the Skin

New data from the international FIELD Study Repeat presented today at the 15th World Congress of Cancers of the Skin (WCCS) in Edinburgh, Scotland, demonstrate initial treatment with Picato® (ingenol mebutate gel) 0.015% is efficacious in treating actinic keratoses (AK) and, when followed by a repeat cycle for persistent and newly emerging AKs, this efficacy is further increased.1 The data also confirm two treatment cycles of Picato® are well tolerated by patients.2

4 Sep 2014

Socio-economic barriers preclude patients from receiving breast conserving therapy

Despite its acceptance as standard of care for early stage breast cancer almost 25 years ago, barriers still exist that preclude patients from receiving breast conserving therapy (BCT), with some still opting for a mastectomy, according to research from The University of Texas MD Anderson Cancer Center.

4 Sep 2014

Current issue provides critical review of data concerned with antidepressant drugs

A paper in the current issue of Psychotherapy and Psychosomatics by Giovanni Fava, MD (University of Bologna) provides a critical review of the data concerned with antidepressant drugs.

4 Sep 2014

Nosopharm reports findings on Odilorhabdins that has potential to combat antibiotic resistance

Nosopharm, a specialist in the research and development of new anti-infective drugs, announces today its in vitro and in vivo findings for a novel antibacterial class, Odilorhabdins, which has the potential to combat antibiotic resistance.

4 Sep 2014

F2G begins F901318 Phase I clinical study for treatment of aspergillus infections

F2G Limited, the antifungal research and development company today announced a major milestone in the development of its novel IV/ oral systemic antifungal (F901318) with the commencement of a Phase I clinical study.

4 Sep 2014

Clinical trial to assess safety and efficacy of novel monoclonal antibody for CLL patients

Researchers at the University of California, San Diego School of Medicine, in partnership with the California Institute for Regenerative Medicine (CIRM) and Celgene Corporation, a New Jersey-based biopharmaceutical company, have launched a phase 1 human clinical trial to assess the safety and efficacy of a novel monoclonal antibody for patients with chronic lymphocytic leukemia (CLL).

4 Sep 2014

Infinity and AbbVie enter into global collaboration to develop and commercialize duvelisib

Infinity Pharmaceuticals, Inc. and AbbVie Inc. today announced that they have entered into a global collaboration to develop and commercialize duvelisib (IPI-145), Infinity's oral inhibitor of phosphoinositide-3-kinase (PI3K)-delta and PI3K-gamma, for the treatment of patients with cancer.

3 Sep 2014

Researchers examine role of blocking vagus nerve in weight loss

Among patients with morbid obesity, blocking the vagus nerve, which plays a role with appetite and metabolism, did not meet pre-specified efficacy objectives compared to a control group, although the intervention did result in greater weight loss, according to a study in the September 3 issue of JAMA.

3 Sep 2014

Yoga program for MS patients improves physical and mental well-being

Paula Meltzer was only 38 when out of nowhere everything she looked at was blurry. For the single mother, who had a lucrative career as a gemologist and spent hours examining valuable pieces of jewelry, it seemed as if - in a split second - her life changed.

3 Sep 2014

ANP reports primary efficacy results from ATL1103 Phase II trial in patients with acromegaly

Antisense Therapeutics Limited is pleased to report the primary efficacy results from its Phase II clinical trial of ATL1103 in patients with the potentially life threatening growth disorder, acromegaly.

2 Sep 2014

BioPhotas launches Celluma ELITE for sale to Aesthetic Physician Market

BioPhotas, Inc. today announced the launch of the Celluma ELITE for sale to the Aesthetic Physician Market. The LED therapy device is stand-mounted and able to be precisely positioned over an area of treatment via an articulating arm and a patented shape-taking light panel.

2 Sep 2014

Amgen seeks EMA approval for marketing talimogene laherparepvec

Amgen today announced the submission of a Marketing Authorization Application (MAA) to the European Medicines Agency (EMA) via the centralized procedure for talimogene laherparepvec seeking approval for the treatment of adults with melanoma that is regionally or distantly metastatic.

2 Sep 2014

Efficacy News and Research

Transparency Life receives SBIR program grant to fund Phase 2a proof-of-concept study for MS

BMC receives grant from Cardinal Health Foundation to help improve effectiveness of patient care

Non-invasive delivery of drugs for effective pain relief

New immuno-oncology drug helps body's own immune system to fend off cancer

New antifungal drug effective against invasive mold disease in cancer patients with less adverse effects

Soligenix acquires novel orphan drug candidate for treatment of CTCL

Scientists apply iPS cell technology to Huntington's disease transgenic monkey model

Combination miRNA therapy offers promising therapeutic avenue for non-small-cell lung cancer

New actinic keratoses data presented at the 15th World Congress of Cancers of the Skin

Socio-economic barriers preclude patients from receiving breast conserving therapy

Current issue provides critical review of data concerned with antidepressant drugs

Nosopharm reports findings on Odilorhabdins that has potential to combat antibiotic resistance

F2G begins F901318 Phase I clinical study for treatment of aspergillus infections

Clinical trial to assess safety and efficacy of novel monoclonal antibody for CLL patients

Infinity and AbbVie enter into global collaboration to develop and commercialize duvelisib

Researchers examine role of blocking vagus nerve in weight loss

Yoga program for MS patients improves physical and mental well-being

ANP reports primary efficacy results from ATL1103 Phase II trial in patients with acromegaly

BioPhotas launches Celluma ELITE for sale to Aesthetic Physician Market

Amgen seeks EMA approval for marketing talimogene laherparepvec

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Latest News